Sage Journals: Discover world-class research

Abstract

Objectives: Age-related hearing loss (ARHL) is a complex disease associated with the interaction of multiple factors. Furthermore, indicators of liver function represent the body’s metabolic, immune, and repair abilities. This study investigated correlations between liver function and ARHL. Methods: A total of 107 patients with ARHL and 107 age- and sex-matched healthy volunteers were included. Linear correlations, logistic regression, and receiving operator characteristic curves were used to assess the associations between liver function and ARHL. Results: Serum prealbumin (PAB) levels were significantly lower in the ARHL group compared to the control group. Logistic regression analysis indicated that low PAB levels may be an independent risk factor for ARHL. The ARHL was divided into 2 groups according to the degree of hearing loss (moderately severe-to-profound and mild-to-moderate); the median ages in the 2 groups were 70.48 and 66.85 years, respectively, with the difference being significant. Age was an independent risk factor for moderately severe-to-profound ARHL, as shown by the logistic regression analysis. Conclusions: Lower PAB levels in patients with ARHL suggested that PAB may be a risk factor for ARHL. Furthermore, higher age in patients with ARHL was associated with a greater degree of hearing loss.

Keywords

Introduction

According to the “World Report on Hearing” published by the World Health Organization (WHO) in 2021, hearing impairment affects more than 1.5 billion people globally, and predictions show that around 2.5 billion people will have experienced some degree of hearing loss by 2025.¹ The most common cause of hearing loss in older adults worldwide is presbycusis, or age-related hearing loss (ARHL).² The WHO estimates that approximately 164.5 million people aged >65 years worldwide had hearing impairment in 2012.³ With the current increasing age of the global population and increasing life expectancy, more than 500 million people over the age of 60 are expected to have ARHL by 2025.⁴

ARHL usually manifests as an irreversible, progressive disorder, with hearing loss beginning in the high-frequency range and gradually progressing to the low-frequency range.⁵ Several recent studies have revealed that ARHL can cause cognitive impairment and that it is an independent high-risk factor for several neuropsychiatric disorders, including dementia, depression, and Alzheimer’s disease.⁶ Uncorrected hearing loss not only affects physical and cognitive functions, but can also result in serious withdrawal from social activities.⁷

Tests of liver function can be used as important indicators of pathological metabolic changes and are extensively used in clinical diagnostics. They represent the metabolic, immunological, and repairing abilities of the body.^8-10 Moreover, there is a higher incidence of liver pathologies, impairing liver function, in older adults.¹¹ Impaired liver function may be a predictive factor for sudden sensorineural hearing loss.¹² A retrospective cohort study showed that the occurrence and development of ARHL are common, patients with high serum albumin (ALB) levels are less likely to experience hearing deterioration, while patients with high blood bilirubin levels show poor prognoses regarding ARHL.¹³ This may be because ALB is an important antioxidant component that has a protective effect on the auditory system. While, bilirubin can directly cause neurotoxic damage to the auditory system after crossing the blood-brain barrier.¹³

Although several studies have explored serum markers as indicators of risk for hearing loss, there have been no studies investigating the relationship between liver function and ARHL. Therefore, this retrospective study analyzed several common indicators, including ALB, globulin (GLB), the albumin-to-globulin ratio (AGR), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin (TBIL), direct bilirubin (DBIL), and prealbumin (PAB), to elucidate whether the indicators are potential risk factors for ARHL. Furthermore, we grouped patients with ARHL according to their degree of hearing loss and analyzed whether liver function indicators could predict the severity of hearing loss in ARHL.

Materials and Methods

Study Population

The present study included 107 patients diagnosed with ARHL from May 2022 to September 2023 at our hospital, with pure-tone average (PTA) values exceeding 20 dB Hearing level (HL) being considered as indicative of hearing impairment. This study enrolled patients with ARHL aged ≥60 years with average PTA values >20 dB HL at 0.125, 0.25, 0.5, 1, 2, 4, and 8 kHz. The exclusion criteria were: (1) the presence of otologic disorders affecting a diagnosis of ARHL, including conductive hearing loss; acoustic trauma or chronic otitis media; ear surgery; or Ménière’s disease; (2) severe organ dysfunction including liver or kidney dysfunction or malignancy that significantly affected liver function; (3) patients with incomplete clinical data; and (4) patients taking drugs that interfere with liver function. We recruited 107 sex- and age-matched older adults with healthy hearing from our regular medical checkup population for comparison. The same exclusion criteria were applied to the control group.

Data Collection

A detailed medical history of baseline characteristics such as sex, age, and body mass index (BMI) was collected. Venous blood samples were collected from all participants between 06:00 and 07:00 after overnight fasting. The blood samples were then subjected to liver function tests using an automated biochemical analyzer. The AGR was calculated by dividing the ALB level by the GLB level. After blood samples were collected, hearing examinations performed on the same day measured air-conducted and bone-conducted PTA at 0.125, 0.25, 0.5, 1, 2, 4, and 8 kHz; the tests were performed by an audiologist in a standardized shielded room. The degree of hearing loss was assessed using average hearing thresholds (0.125-8 kHz) for the frequencies damaged in both ears.

Statistical Analysis

SPSS 27.0 (IBM Corp) and GraphPad Prism 9.0 (GraphPad Software) were used for all statistical analyses. Descriptive variables in this study are presented as median (interquartile range), mean ± standard deviation, or percentage. The means of normally distributed variables were compared using unpaired t tests. The medians of nonnormally distributed continuous variables were compared using the Mann-Whitney U test. To compare categorical variables, the chi-squared test was used. To analyze linear correlations and to create scatter plots of associating liver function parameters and hearing loss severity, Spearman’s correlation analysis was used. After the collinearity of all continuous variables was examined using variance inflation factors, backward conditional logistic regression analyses were performed to assess the odds ratios (ORs) and 95% confidence intervals (CIs) for the correlations between liver function parameters and ARHL. Correlations between liver function parameters and different degrees of hearing loss were also assessed using logistic regression, as described above. To identify the most significant factor associated with ARHL and to determine a cutoff value, receiver operating characteristic curve analysis was performed. P values <.05 were considered statistically significant in all tests.

Results

Clinical Characteristics

A total of 107 patients with ARHL and 107 age- and sex-matched healthy participants were included. There were no significant differences in age, sex, or BMI between the 2 groups (Table 1). The ARHL group showed significantly higher GLB and DBIL levels than the control group (P < .05). Conversely, PAB and AGR levels were lower in the ARHL group than in the control group (P < .05). There were no statistically significant differences between the groups for ALB or other liver function indicators (all P > .05).

Table 1.

Clinical Characteristics of the ARHL and Control Groups.

Variables	ARHL (n = 107)	Control (n = 107)	P value
Baseline characteristics
Age (years)	69.13 ± 6.72	68.64 ± 6.58	.601
Sex (male, %)	51 (47.66%)	54 (50.47%)	.682
BMI (kg/m²)	22.93 (21.12-24.48)	23.36 (20.91-25.13)	.262
Laboratory variables
ALB (g/L)	46.00 (44.10-47.30)	46.40 (44.90-47.90)	.059
GLB (g/L)	27.60 (25.70-29.80)	25.80 (24.30-28.20)	.003**
AGR	1.70 (1.50-1.80)	1.80 (1.60-2.00)	.002**
ALT (U/L)	20.00 (15.00-26.00)	21.00 (16.00-28.00)	.196
AST (U/L)	22.00 (19.00-27.00)	23.00 (20.00-26.00)	.368
ALP (U/L)	74.00 (62.00-90.00)	75.00 (62.00-88.00)	.750
TBIL (μmol/L)	11.00 (8.60-14.10)	10.70 (8.30-13.90)	.789
DBIL (μmol/L)	3.20 (2.50-4.10)	2.80 (1.90-3.50)	.009**
PAB (mg/L)	253.00 (237.00-276.00)	269.00 (245.00-300.00)	.002**

Abbreviations: AGR, albumin-to-globulin ratio; ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; ARHL, age-related hearing loss; AST, aspartate aminotransferase; BMI, body mass index; DBIL, direct bilirubin; GLB, globulin; PAB, prealbumin; TBIL, total bilirubin.

P < .01.

Correlation Between ARHL and Liver Function Parameters

As shown in Figure 1, PAB levels were negatively and linearly correlated with ARHL. Next, we constructed logistic regression models on the basis of the liver function parameters (Table 2), with the AGR being precluded due to collinearity between all continuous variables, as assessed by the variance inflation factor. In the univariate logistic regression analysis, with unadjusted ORs of 0.888 (95% CI, 0.796-0.990; P < .05), 1.095 (95% CI, 1.016-1.181; P < .05), and 0.987 (95% CI, 0.980-0.995; P < .01), serum ALB, GLB, and PAB levels were strongly correlated with the incidence of ARHL. When adjusted for all the other variables (with age, sex, BMI, ALB, ALT, AST, ALP, TBIL, and DBIL gradually excluded from the multivariate analysis), PAB levels remained an independent predictor of ARHL, with an adjusted OR of 0.988 (95% CI, 0.980-0.996; P < .01). To detect the most significant factors related to the presence of ARHL and to determine a cutoff value, receiver operating characteristic curve analysis was used (Figure 2). However, the areas under the curve were all less than 0.7, suggesting that the AGR and levels of ALB, GLB, TBIL, DBIL, and PAB were imperfect predictors of ARHL.

Figure 1.

Plots of liver function marker levels versus ARHL severity. (A-I) Represent the relationship between ALB, GLB, AGR, ALT, AST, ALP, TBIL, DBIL, and PAB with ARHL severity, respectively. *P < .05. AGR, albumin-to-globulin ratio; ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; ARHL, age-related hearing loss; AST, aspartate aminotransferase; DBIL, direct bilirubin; GLB, globulin; PAB, prealbumin; TBIL, total bilirubin.

Table 2.

Binary Logistic Regression Analysis of the Relationship Between Liver Function Levels and ARHL.

Parameter	Univariate analysis			Multivariate analysis
Parameter	OR	95% CI	P value	OR	95% CI	P value
Predictor: occurrence of disease
Age (years)	1.011	0.971-1.053	.599
Sex (male, %)	1.119	0.654-1.913	.682
BMI (kg/m²)	0.936	0.830-1.056	.281
ALB (g/L)	0.888	0.796-0.990	.033*
GLB (g/L)	1.095	1.016-1.181	.018*	1.075	0.994-1.163	.069
ALT (U/L)	0.984	0.955-1.013	.281
AST (U/L)	0.994	0.956-1.033	.744
ALP (U/L)	1.002	0.988-1.016	.783
TBIL (μmol/L)	0.999	0.945-1.056	.966
DBIL (μmol/L)	1.142	0.957-1.363	.141
PAB (mg/L)	0.987	0.980-0.995	<.001**	0.988	0.980-0.996	.003**

Age, sex, BMI, ALB, ALT, AST, ALP, TBIL, and DBIL were gradually excluded from the multivariate analysis.

Abbreviations: ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; ARHL, age-related hearing loss; AST, aspartate aminotransferase; BMI, body mass index; CI, confidence interval; DBIL, direct bilirubin; GLB, globulin; OR, odds ratio; PAB, prealbumin; TBIL, total bilirubin.

P < .05, **P < .01.

Figure 2.

ROC curve analysis of ALB, GLB, AGR, TBIL, DBIL, and PAB levels for the prediction of ARHL. (A-F) represent ROC curves for ALB, GLB, AGR, TBIL, DBIL, and PAB levels, respectively, for the prediction of the occurrence of ARHL. **P < .01. AGR, albumin-to-globulin ratio; ALB, albumin; ARHL, age-related hearing loss; AUC, area under the curve; CI, confidence interval; DBIL, direct bilirubin; GLB, globulin; PAB, prealbumin; ROC, receiver operating characteristic; TBIL, total bilirubin.

Moderately Severe-to-Profound ARHL and Liver Function Parameters

According to the latest WHO report on hearing, hearing loss of over 50 dB qualifies as “moderately severe-to-profound hearing loss,” which means that people with this hearing loss have difficulty hearing during normal conversation.¹ Hence, patients with ARHL were divided into 2 subgroups based on ARHL severity: a moderately severe-to-profound subgroup, with hearing loss >50 dB, and a mild-to-moderate hearing loss subgroup, with hearing loss ≤50 dB. Table 3 shows the baseline characteristics and liver function parameters of both ARHL subgroups. The median ages in the moderately severe-to-profound and mild-to-moderate subgroups were 70.48 and 66.85 years, respectively (P < .01). However, there were no significant differences between the 2 subgroups in terms of liver function markers, and we included all factors from the correlation analysis in the regression model. The variance inflation factor was used to eliminate the AGR due to collinearity with all continuous variables. In the univariate logistic regression analysis, with an unadjusted OR of 1.093 (95% CI, 1.023-1.167; P < .01), patient age showed a strong association with moderately severe-to-profound ARHL severity. When adjusted for all the other variables (sex, BMI, and ALB, GLB, ALT, AST, ALP, TBIL, DBIL, and PAB levels were gradually excluded from the multivariate analysis), age was an independent risk factor for the severity of ARHL with an adjusted OR of 1.105 (95% CI, 1.013-1.185; P < .01; Table 4).

Table 3.

Baseline Characteristics of Participants in the Moderately Severe-to-Profound ARHL and Mild-to-Moderate ARHL Groups.

Variables	Moderately severe-to-profound ARHL (n = 67)	Mild-to-moderate (n = 40)	P value
Baseline characteristics
Age (years)	70.48 ± 7.00	66.85 ± 5.58	.006**
Sex (male, %)	36 (53.73%)	15 (37.50%)	.104
BMI (kg/m²)	22.58 (20.60-24.47)	23.28 (22.28-24.66)	.114
Laboratory variables
ALB (g/L)	45.70 (44.00-47.50)	46.30 (44.10-47.18)	.694
GLB (g/L)	27.60 (26.00-30.20)	27.45 (23.90-29.70)	.404
AGR	1.70 (1.50-1.80)	1.70 (1.50-1.90)	.225
ALT (U/L)	19.00 (14.00-26.00)	20.50 (15.00-27.50)	.237
AST (U/L)	23.00 (20.00-28.00)	22.00 (19.00-26.75)	.296
ALP (U/L)	75.00 (62.00-93.00)	73.50 (62.50-81.75)	.423
TBIL (μmol/L)	10.90 (8.30-14.10)	11.0 (9.33-14.08)	.518
DBIL (μmol/L)	3.20 (2.50-4.20)	3.00 (2.50-3.98)	.629
PAB (mg/L)	251.00 (232.00-273.00)	256.00 (248.25-278.75)	.097

P < .01.

Table 4.

Binary Logistic Regression Analysis of the Relationship Between Liver Function Marker Levels and ARHL Severity.

Parameter	Univariate analysis			Multivariate analysis
Parameter	OR	95% CI	P value	OR	95% CI	P value
Predictor: occurrence of moderately severe-to-profound disease
Age (years)	1.093	1.023-1.167	.008*	1.105	1.013-1.185	.005**
Sex (male, %)	0.517	0.232-1.150	.106
BMI (kg/m²)	0.860	0.715-1.035	.110
ALB (g/L)	0.944	0.803-1.110	.486
GLB (g/L)	1.049	0.939-1.172	.400
ALT (U/L)	0.971	0.929-1.015	.196
AST (U/L)	0.998	0.947-1.052	.943
ALP (U/L)	1.010	0.990-1.030	.315
TBIL (μmol/L)	0.988	0.911-1.071	.771
DBIL (μmol/L)	1.028	0.770-1.374	.849
PAB (mg/L)	0.991	0.979-1.003	.132

Sex, BMI, ALB, GLB, ALT, AST, ALP, TBIL, DBIL, and PAB were gradually excluded from the multivariate analysis.

P < .01.

Discussion

ARHL is a progressive and degenerative disease, and most of the causes of its development are unknown. The proportion of people with ARHL is likely to increase as a result of the aging of the global population. As the body ages, the auditory system undergoes various changes. Various components of the inner ear, including hair cells, vascular strips, spiral bands, and auditory nerve fibers, experience irreversible degradation, which affects the transmission of ions and signals.¹⁴ In addition, decreased immune function causes persistent chronic inflammation, and decreased enzymatic activity diminishes the ability of the body to remove toxins, which can ultimately result in hearing loss.^15-17

ARHL and other age-related diseases share common etiologies and often involve low-grade chronic inflammation, a relationship referred to as “inflammaging.” Aging can lead to immune system dysfunction, resulting in an accumulation of unresolved inflammation in the body.¹⁸ Several molecular pathways have been identified that are linked to aging and low-grade inflammation, such as the inflammasome, which may be triggered by age-related oxidative stress; clustering of senescent cells; and reduced autophagic activation.¹⁹ Inflammation has been identified as a pathophysiological mechanism contributing to ARHL in numerous preclinical and population-based medical research studies.²⁰ Aging cochleae show increased levels of interleukin-1 beta and tumor necrosis factor alpha.²¹ In addition, genetic variations in genes related to inflammatory mediators were shown to be associated with an increased risk of hearing loss in a study in older Japanese adults.^22,23 Verschuur et al²³ reported that the expression of systemic inflammation-related markers, such as C-reactive protein, interleukin-6, neutrophils, and leukocytes, was upregulated in patients with ARHL and correlated with the degree of hearing impairment. Lassale et al,²⁴ in the English Longitudinal Study of Aging, also found a correlation between hearing loss and white blood cell counts.

The main finding of the present study is that low serum PAB levels were an independent risk factor for ARHL. PAB, also called transthyretin, plays an important role in the transport of thyroxine and retinol and is synthesized mainly by the liver.²⁵ Recent clinical studies investigating PAB have found that serum levels of PAB were downregulated in different pathological conditions such as inflammation, protein malnutrition, end-stage liver disease, and malignancy.²⁶ In addition, serum PAB levels may be predictive of respiratory diseases, burns, systemic sclerosis, and cardiac surgery.^27-30 Serum PAB levels are negatively correlated with stroke severity in young individuals and are significantly reduced in patients who experience recurrent ischemic stroke.^31,32 Although the biological mechanisms and the role of serum PAB in ARHL are unknown, we hypothesize that these associations are mediated by several pathways.

First, the association between PAB levels and ARHL is likely correlated with the inflammatory response. Notably, inflammation plays an important role in neurological disorders such as stroke, Parkinson’s disease, and Alzheimer’s disease, where low levels of PAB have been found, suggesting that serum PAB levels are negatively correlated with the severity of inflammation.³³ Patients with chronic pancreatitis have lower levels of PABs than healthy people, often indicating protein-calorie malnutrition.³⁴ PAB is believed to function within the immune system as a component of the enhanced cytokine system, exerting suppressive influences on inflammation.³⁵ Thus, low PAB levels indicate activation of systemic inflammation.³⁶ Therefore, this could also explain that, in our study, serum PAB levels were higher in the healthy control group than in the ARHL group. The anti-inflammatory effect of PAB may play an important role in the development of ARHL.

Second, the absence of hair cells and spiral ganglion neurons, reductions in the number of synaptic connections between auditory neurons, thinning of the auditory cortex, and reductions in gray matter volume were all found to be related to the development of hearing impairment in ARHL.^37-40 This suggests that ARHL is inextricably linked to neural remodeling, and recent studies have shown that PAB improves nerve regeneration.^41,42 Thus, low PAB levels may also adversely affect the development of ARHL by interfering with nerve regeneration.

Third, increasing evidence links oxidative stress with ARHL.²¹ The development of ARHL is influenced by a combination of aging, comorbidities, lifestyle, and environmental and genetic factors,⁴³ and these factors increase the generation and accumulation of reactive oxygen species (ROS) in the body.⁴⁴ In addition, studies on oxidative senescence have suggested that the decline in function associated with aging is caused by damage to DNA, lipids, and/or proteins due to the accumulation of ROS.⁴⁵ In the mouse cochlea, aging was found to be associated with lipid peroxidation, oxidative DNA damage, and reduced expression of glutathione-binding proteins, as well as catalase and other antioxidant enzymes.^46,47 Clinical studies have found that the prevalence of high-frequency hearing loss in older adults correlated significantly with reduced serum levels of melatonin, an ROS scavenger.⁴⁸ Interestingly, recent articles have identified PAB as a protein with a very high susceptibility to modification and oxidation and as a potential biomarker for monitoring ROS imbalance under different oxidative stress scenarios.⁴⁹ Therefore, the pathological mechanisms associated with ROS may be another reason for the usefulness of the PAB level as an indicator for ARHL.

The present results also suggested that higher age is a risk factor for the severity of ARHL. The incidence of hearing loss doubles in each decade of life starting with the second decade.⁵⁰ Furthermore, the incidence of hearing impairment with a moderate (or greater) severity is also positively correlated with age worldwide, with numbers surging from 15.4% in individuals aged 60 to 69 years to 58.2% in those aged >90 years.¹ Thus, long-term exposure to multiple risk factors for hearing loss causes the ear to accumulate more and more damage throughout the life cycle, which has a significant effect on the development and progression of ARHL.

Limitations

The present study had some limitations. First, as a preliminary study, the reproducibility and validity of the results need to be confirmed in future studies. Second, despite the use of strict inclusion and exclusion criteria, this was a single-center trial with a limited number of participants, and the findings may have been influenced by selection bias. Third, markers of liver function were measured only during study enrollment, and long-term assessments and follow-ups regarding these values and hearing ability were lacking in this study. A more comprehensive long-term assessment should be performed to accurately reflect the final hearing status of patients with ARHL.

Conclusions

In summary, this study investigated the relationships between ARHL and markers of liver function. PAB levels were negatively correlated with the degree of hearing loss, and lower PAB levels may be a risk factor for ARHL. In addition, age was an independent risk factor predicting the severity of ARHL. Therefore, these findings provide insight into preventive strategies for ARHL. Larger prospective clinical studies and further basic research are needed to validate our findings and explore the exact pathological mechanisms.

Footnotes

Acknowledgements

Thanks to all study participants.

Author Contributions

Di Qian designed and supervised the study. Yanmei Feng and Haibo Shi provided suggestions on data collection and evaluation. Yemeng He, Lin Zhou, and Quanran Lin analyzed the data. Liang Xia and Xiaoyan Chen wrote the manuscript. Tao Wang and Ying Wang participated in revising the manuscript. All authors approved the final version.

Availability of Data and Materials

The raw data supporting the conclusions of this article have been provided by the authors without undue restriction.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by the First Grant (2020YFC2005201) of the Chinese National Key Research and Development Programme (2020YFC2005200), the National Natural Science Foundation of China (82171139, 82371152), and the Shanghai Municipal Commission of Science and Technology (18DZ2260200).

Ethical Approval

This study was reviewed and approved by the Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (2021-218-[1]). The research process was fully compliant with the Declaration of Helsinki, and all participants provided written informed consent.

ORCID iDs

Liang Xia

Xiaoyan Chen

References

WHO. World report on hearing. 2021. Accessed March 3, 2021. https://www.who.int/publications/i/item/9789240020481

Yang

Zhao

Chai

Fan

. Progress on mechanisms of age-related hearing loss. Front Neurosci. 2023;17:1253574. doi:10.3389/fnins.2023.1253574

Sheffield

Smith

RJH

. The epidemiology of deafness. Cold Spring Harb Perspect Med. 2019;9(9):a033258. doi:10.1101/cshperspect.a033258

Wang

Puel

. Presbycusis: an update on cochlear mechanisms and therapies. J Clin Med. 2020;9(1):218. doi:10.3390/jcm9010218

Wangemann

. Supporting sensory transduction: cochlear fluid homeostasis and the endocochlear potential. J Physiol. 2006;576(Pt 1):11-21. doi:10.1113/jphysiol.2006.112888

Lin

Yaffe

Xia

, et al Hearing loss and cognitive decline in older adults. JAMA Intern Med. 2013;173(4):293-299. doi:10.1001/jamainternmed.2013.1868

Prieur Chaintré

Couturier

Nguyen

THT

Levasseur

. Influence of hearing loss on social participation in older adults: results from a scoping review. Res Aging. 2024;46(1):72-90. doi:10.1177/01640275231174561

Ranasinghe

Biswas

Vincent

. Prealbumin: the clinical utility and analytical methodologies. Ann Clin Biochem Int J Lab Med. 2022;59(1):7-14. doi:10.1177/0004563220931885

Rothschild

Oratz

Schreiber

. Serum albumin. Hepatology. 1988;8(2):385-401. doi:10.1002/hep.1840080234

10.

Demeli

Meyer

. The assessment of haematologic and serum chemistry parameters in canine pyometra: a systematic review and meta-analysis. J Small Anim Pract. 2023;64(9):543-551. doi:10.1111/jsap.13641

11.

Schmucker

. Age-related changes in liver structure and function: implications for disease ? Exp Gerontol. 2005;40(8-9):650-659. doi:10.1016/j.exger.2005.06.009

12.

Zheng

Liu

Shen

, et al Serum albumin levels as a potential marker for the predictive and prognostic factor in sudden sensorineural hearing loss: a prospective cohort study. Front Neurol. 2021;12:747561.

13.

Moon

Byun

Woo

, et al Factors associated with age-related hearing impairment: a retrospective cohort study. Medicine (Baltimore). 2015;94(43):e1846. doi:10.1097/MD.0000000000001846

14.

Seidman

Ahmad

Bai

. Molecular mechanisms of age-related hearing loss. Ageing Res Rev. 2002;1(3):331-343. doi:10.1016/S1568-1637(02)00004-1

15.

Eckert

Harris

Lang

, et al Translational and interdisciplinary insights into presbyacusis: a multidimensional disease. Hear Res. 2021;402:108109. doi:10.1016/j.heares.2020.108109

16.

Tawfik

Klepper

Saliba

Friedman

. Advances in understanding of presbycusis. J Neurosci Res. 2020;98(9):1685-1697. doi:10.1002/jnr.24426

17.

Lang

Ebihara

Schmiedt

, et al Contribution of bone marrow hematopoietic stem cells to adult mouse inner ear: mesenchymal cells and fibrocytes. J Comp Neurol. 2006;496(2):187-201. doi:10.1002/cne.20929

18.

Kociszewska

Vlajkovic

. Age-related hearing loss: the link between inflammaging, immunosenescence, and gut dysbiosis. Int J Mol Sci. 2022;23(13):7348. doi:10.3390/ijms23137348

19.

Kujoth

Hiona

Pugh

, et al Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science. 2005;309(5733):481-484. doi:10.1126/science.1112125

20.

Paplou

Schubert

NMA

Pyott

. Age-related changes in the cochlea and vestibule: shared patterns and processes. Front Neurosci. 2021;15:680856. doi:10.3389/fnins.2021.680856

21.

Menardo

Tang

Ladrech

, et al Oxidative stress, inflammation, and autophagic stress as the key mechanisms of premature age-related hearing loss in SAMP8 mouse cochlea. Antioxid Redox Signal. 2012;16(3):263-274. doi:10.1089/ars.2011.4037

22.

Uchida

Sugiura

Sone

Ueda

Nakashima

. Progress and prospects in human genetic research into age-related hearing impairment. Biomed Res Int. 2014;2014:1-10. doi:10.1155/2014/390601

23.

Verschuur

Dowell

Syddall

, et al Markers of inflammatory status are associated with hearing threshold in older people: findings from the Hertfordshire ageing study. Age Ageing. 2012;41(1):92-97. doi:10.1093/ageing/afr140

24.

Lassale

Vullo

Cadar

Batty

Steptoe

Zaninotto

. Association of inflammatory markers with hearing impairment: the English Longitudinal Study of Ageing. Brain Behav Immun. 2020;83:112-119. doi:10.1016/j.bbi.2019.09.020

25.

Wang

Ren

, et al Low serum prealbumin levels in post-stroke depression. Psychiatry Res. 2016;246:149-153. doi:10.1016/j.psychres.2016.09.021

26.

Ingenbleek

Young

. Transthyretin (prealbumin) in health and disease: nutritional implications. Annu Rev Nutr. 1994;14(1):495-533. doi:10.1146/annurev.nu.14.070194.002431

27.

Codullo

Cereda

Klersy

, et al Serum prealbumin is an independent predictor of mortality in systemic sclerosis outpatients. Rheumatology. 2016;55(2):315-319. doi:10.1093/rheumatology/kev322

28.

Yang

Yim

Cho

, et al Serum transthyretin level is associated with clinical severity rather than nutrition status in massively burned patients. J Parenter Enter Nutr. 2014;38(8):966-972. doi:10.1177/0148607113499588

29.

Le Bricon

Guidet

Coudray-Lucas

, et al Biochemical assessment of nutritional status in patients with chronic obstructive pulmonary disease and acute respiratory failure on admission to an intensive care unit. Clin Nutr. 1994;13(2):98-104. doi:10.1016/0261-5614(94)90067-1

30.

Cassiere

Dellis

Manetta

Kohn

Hartman

. Impact of preoperative prealbumin on outcomes after cardiac surgery. J Parenter Enter Nutr. 2015;39(7):870-874. doi:10.1177/0148607114536735

31.

Gao

Zhang

Yin

Gao

. Serum prealbumin (transthyretin) predict good outcome in young patients with cerebral infarction. Clin Exp Med. 2011;11(1):49-54. doi:10.1007/s10238-010-0103-8

32.

Zhang

Shu

Zhang

Tong

. Dynamics of nutritional status in dying patients with acute cerebral infarction in central China: a preliminary study. Neurol Res. 2011;33(5):503-507. doi:10.1179/016164111X13007856084160

33.

Fleming

Nunes

Sousa

. Transthyretin: more than meets the eye. Prog Neurobiol. 2009;89(3):266-276. doi:10.1016/j.pneurobio.2009.07.007

34.

Greer

Sandhu

, et al Nutrition and inflammatory biomarkers in chronic pancreatitis patients. Nutr Clin Pract. 2019;34(3):387-399. doi:10.1002/ncp.10186

35.

Lögdberg

Wester

. Immunocalins: a lipocalin subfamily that modulates immune and inflammatory responses. Biochim Biophys Acta. 2000;1482(1-2):284-297. doi:10.1016/S0167-4838(00)00164-3

36.

Dickson

Howlett

Schreiber

. Metabolism of prealbumin in rats and changes induced by acute inflammation. Eur J Biochem. 1982;129(2):289-293. doi:10.1111/j.1432-1033.1982.tb07051.x

37.

Rigters

Bos

Metselaar

, et al Hearing impairment is associated with smaller brain volume in aging. Front Aging Neurosci. 2017;9:2. doi:10.3389/fnagi.2017.00002

38.

Giroud

Lemke

Reich

Matthes

Meyer

. The impact of hearing aids and age-related hearing loss on auditory plasticity across three months—an electrical neuroimaging study. Hear Res. 2017;353:162-175. doi:10.1016/j.heares.2017.06.012

39.

Ren

, et al Gray matter atrophy is associated with cognitive impairment in patients with presbycusis: a comprehensive morphometric study. Front Neurosci. 2018;12:744. doi:10.3389/fnins.2018.00744

40.

Liu

Zhang

Fan

, et al Potential role of Bcl2 in lipid metabolism and synaptic dysfunction of age-related hearing loss. Neurobiol Dis. 2023;187:106320. doi:10.1016/j.nbd.2023.106320

41.

Fleming

Saraiva

Sousa

. Transthyretin enhances nerve regeneration: transthyretin enhances nerve regeneration. J Neurochem. 2007;103(2):831-839. doi:10.1111/j.1471-4159.2007.04828.x

42.

Slade

Plack

Nuttall

. The effects of age-related hearing loss on the brain and cognitive function. Trends Neurosci. 2020;43(10):810-821. doi:10.1016/j.tins.2020.07.005

43.

Tang

Tran

Dawes

Gopinath

. A narrative review of lifestyle risk factors and the role of oxidative stress in age-related hearing loss. Antioxidants. 2023;12(4):878. doi:10.3390/antiox12040878

44.

Falasca

Greco

Ralli

. Noise induced hearing loss: the role of oxidative stress. Otolaryngol Open J. 2017;SE(5):S1-S5.

45.

Pacher

Beckman

Liaudet

. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007;87(1):315-424. doi:10.1152/physrev.00029.2006

46.

Someya

Kondo

, et al Age-related hearing loss in C57BL/6J mice is mediated by Bak-dependent mitochondrial apoptosis. Proc Natl Acad Sci U S A. 2009;106(46):19432-19437. doi:10.1073/pnas.0908786106

47.

Jiang

Talaska

Schacht

Sha

. Oxidative imbalance in the aging inner ear. Neurobiol Aging. 2007;28(10):1605-1612. doi:10.1016/j.neurobiolaging.2006.06.025

48.

Lasisi

Fehintola

. Correlation between plasma levels of radical scavengers and hearing threshold among elderly subjects with age-related hearing loss. Acta Otolaryngol (Stockh). 2011;131(11):1160-1164. doi:10.3109/00016489.2010.549840

49.

Pereira

Minamino

Takao

. Free thiol of transthyretin in human plasma most accessible to modification/oxidation. Anal Chem. 2015;87(21):10785-10791. doi:10.1021/acs.analchem.5b03431

50.

Bowl

Dawson

. Age-related hearing loss. Cold Spring Harb Perspect Med. 2019;9(8):a033217. doi:10.1101/cshperspect.a033217

Serum Prealbumin as a Potential Predictive Factor for Age-Related Hearing Loss: A Retrospective Study

Abstract

Keywords

Introduction

Materials and Methods

Study Population

Data Collection

Statistical Analysis

Results

Clinical Characteristics

Correlation Between ARHL and Liver Function Parameters

Moderately Severe-to-Profound ARHL and Liver Function Parameters

Discussion

Limitations

Conclusions

Footnotes

Acknowledgements

Author Contributions

Availability of Data and Materials

Declaration of Conflicting Interests

Funding

Ethical Approval

ORCID iDs

References